Reviewing Janone (NASDAQ:ALTS) & Connect Biopharma (NASDAQ:CNTB)

Janone (NASDAQ:ALTS) and Connect Biopharma (NASDAQ:CNTB) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Earnings and Valuation

This table compares Janone and Connect Biopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janone	$7.11 million	13.46	-$7.81 million	N/A	N/A
Connect Biopharma	$24.12 million	2.57	-$59.50 million	N/A	N/A

Janone has higher earnings, but lower revenue than Connect Biopharma.

Risk & Volatility

Janone has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.44, indicating that its stock price is 144% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Janone and Connect Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janone	0	0	0	0	0.00
Connect Biopharma	0	0	1	0	3.00

Connect Biopharma has a consensus price target of $8.00, suggesting a potential upside of 614.29%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Janone.

Profitability

This table compares Janone and Connect Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Janone	N/A	-2,940.01%	-39.81%
Connect Biopharma	N/A	N/A	N/A

Institutional and Insider Ownership

6.3% of Janone shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 4.9% of Janone shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Connect Biopharma beats Janone on 8 of the 11 factors compared between the two stocks.

About Janone

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company’s lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.